Biguanides, thiazolidinediones — Competitive Intelligence Brief

Biguanides, thiazolidinediones (Biguanides, thiazolidinediones) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination therapy. Area: Diabetes.

phase 3 Antidiabetic combination therapy PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component) Diabetes Small molecule

Target snapshot

Biguanides, thiazolidinediones (Biguanides, thiazolidinediones) — University of Pittsburgh. This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biguanides, thiazolidinediones TARGET	Biguanides, thiazolidinediones	University of Pittsburgh	phase 3	Antidiabetic combination therapy	PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component)
Metformin + Insulin	Metformin + Insulin	University of Virginia	marketed	Antidiabetic combination therapy	AMPK (metformin); Insulin receptor (insulin)
Metformin, glyburide and insulin	Metformin, glyburide and insulin	Université de Sherbrooke	phase 3	Antidiabetic combination therapy (biguanide + sulfonylurea + insulin)
Metformin + Intermittent Insulin Therapy	Metformin + Intermittent Insulin Therapy	Mount Sinai Hospital, Canada	phase 3	Antidiabetic combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination therapy class)

1. Mount Sinai Hospital, Canada · 1 drug in this class
2. University of Pittsburgh · 1 drug in this class
3. University of Virginia · 1 drug in this class